Target Name: DNAJC12
NCBI ID: G56521
Other Name(s): HPANBH4 | DnaJ heat shock protein family (Hsp40) member C12, transcript variant 1 | J domain containing protein 1 (JDP1) | J domain protein 1 | DJC12_HUMAN | OTTHUMP00000019690 | DnaJ (Hsp40) homolog, subfamily C, member 12 | DnaJ homolog subfamily C member 12 (isoform a) | DnaJ homolog subfamily C member 12 | DnaJ heat shock protein family (Hsp40) member C12 | j domain-containing protein 1 | JDP1 | DNAJC12 variant 1 | RP11-57G10.2 | J domain-containing protein 1 | OTTHUMP00000019689

DNAJC12: A Promising Drug Target for Neurological Disorders

DNAJC12 (HPANBH4) is a protein that is expressed in various tissues throughout the body, including muscle, liver, and brain. It is a key regulator of the nervous system and has been implicated in a number of neurological and psychiatric disorders.

One of the most promising aspects of DNAJC12 is its potential as a drug target. Several studies have identified potential drug-like compounds that can interact with DNAJC12 and enhance its activity, suggesting that it may be a promising target for the treatment of a range of neurological and psychiatric disorders.

One of the key compounds that has been shown to interact with DNAJC12 is valproic acid, a compound that is commonly used as a treatment for epilepsy and bipolar disorder. Studies have shown that valproic acid can enhance the activity of DNAJC12 and increase the levels of the protein in brain cells.

Another potential drug that may interact with DNAJC12 is lithium, a compound that is commonly used as a treatment for bipolar disorder. Studies have shown that lithium can also enhance the activity of DNAJC12 and increase the levels of the protein in brain cells.

In addition to valproic acid and lithium, a number of other compounds have also been shown to interact with DNAJC12 and enhance its activity. These compounds include neurotransmitters, antidepressants, antipsychotics and hypnotics.

While the potential use of DNAJC12 as a drug target is an exciting area of 鈥嬧?媟esearch, it is important to note that the safety and effectiveness of any potential drug DNAJC12 must be carefully evaluated before it can be approved for use. Additionally, it is also important to consider the potential interactions of any drugs with DNAJC12 and other proteins in the body.

Overall, DNAJC12 is a protein that has the potential to be a drug target for the treatment of a range of neurological and psychiatric disorders. Further research is needed to fully understand its potential and to develop safe and effective drugs that can interact with DNAJC12.

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member C12

More Common Targets

DNAJC13 | DNAJC14 | DNAJC15 | DNAJC16 | DNAJC17 | DNAJC17P1 | DNAJC18 | DNAJC19 | DNAJC2 | DNAJC21 | DNAJC22 | DNAJC24 | DNAJC25 | DNAJC25-GNG10 | DNAJC27 | DNAJC27-AS1 | DNAJC28 | DNAJC3 | DNAJC3-DT | DNAJC30 | DNAJC4 | DNAJC5 | DNAJC5B | DNAJC5G | DNAJC6 | DNAJC7 | DNAJC8 | DNAJC8P3 | DNAJC9 | DNAJC9-AS1 | DNAL1 | DNAL4 | DNALI1 | DNASE1 | DNASE1L1 | DNASE1L2 | DNASE1L3 | DNASE2 | DNASE2B | DND1 | DNER | DNHD1 | DNLZ | DNM1 | DNM1L | DNM1P33 | DNM1P35 | DNM1P41 | DNM1P46 | DNM1P49 | DNM2 | DNM3 | DNM3OS | DNMBP | DNMBP-AS1 | DNMT1 | DNMT1-G9a-PCNA complex | DNMT1-HDAC2-DMAP1 complex | DNMT1-Rb-E2F1-HDAC1 complex | DNMT3A | DNMT3AP1 | DNMT3B | DNMT3L | DNPEP | DNPH1 | DNTT | DNTTIP1 | DNTTIP2 | DOC2A | DOC2B | DOC2GP | DOCK1 | DOCK10 | DOCK11 | DOCK2 | DOCK3 | DOCK4 | DOCK4-AS1 | DOCK5 | DOCK6 | DOCK7 | DOCK8 | DOCK8-AS1 | DOCK9 | DOCK9-DT | DOHH | DOK1 | DOK2 | DOK3 | DOK4 | DOK5 | DOK6 | DOK7 | Dolichol-phosphate-mannose synthase complex | DOLK | DOLPP1 | DONSON | DOP1A | DOP1B | Dopamine receptor